Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853431 | 0.89 | MAPT (0.53) | SLC6A2SLC6A4ALDH1A1KMT2AKDM4E | |
| SCHEMBL13665268 | 0.78 | SLC6A2 (1.00) | SLC6A2SLC6A4ALDH1A1KMT2AMAPT | |
| SCHEMBL78465 | 0.76 | ALDH1A1 (0.65) | ALDH1A1HPGDDDB1CRBNL3MBTL1 | |
| SCHEMBL4711615 | 0.75 | MAPT (0.44) | SLC6A2SLC6A4ALDH1A1KMT2AKDM4E | |
| SCHEMBL8340776 | 0.75 | L3MBTL1 (0.56) | SLC6A2SLC6A4KMT2AHPGDMEN1 | |
| SCHEMBL85175 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2AKDM4EMAPTGAA | |
| SCHEMBL12499581 | 0.74 | SLC6A2 (0.49) | SLC6A2SLC6A4ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL157609 | 0.74 | SLC6A2 (0.56) | SLC6A2SLC6A4ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL30962721 | 0.74 | KMT2A (0.56) | SLC6A2ALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL12499505 | 0.74 | SLC6A2 (0.49) | SLC6A2SLC6A4ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009119528-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | TFPI, F2, TFPI2 | SLC6A2 1946/4885SLC6A4 1366/4885ALDH1A1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.